PPARα Agonists for Organ Preservation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological agents are ineffective in preserving organs for transplantation, leading to issues like primary graft dysfunction and limited availability of donors, with no effective treatment for acute organ failure.
Innovation Solution
Administration of a peroxisome-proliferator activated receptor-alpha (PPARα) agonist, such as gemfibrozil, in combination with a cell-impermeable solute like mannitol, to enhance organ preservation and reduce damage during transplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacological agents are used in organ preservation, then the number of available drugs is limited, but the effectiveness in preserving organs is insufficient
Solution Approach 1:
The patent changes the pharmacological parameter by introducing PPARα agonists (fibrate derivatives) into the organ preservation solution, which fundamentally alters the mechanism of action from conventional agents. This parameter change enables effective organ preservation through activation of PPARα, leading to reduced inflammation, apoptosis, and improved cellular survival, thereby resolving the contradiction between limited drug effectiveness and the need for reliable preservation agents
2Duration of action of moving object
If no effective preserving drugs are added to preservation solutions, then the solution composition remains simple, but the graft survival time is limited
Solution Approach 1:
The patent segments the preservation solution into functional components: the base preservation solution (containing mannitol, glucose, and other standard agents) and the additive PPARα agonist. This segmentation allows the complex mechanism of PPARα activation to be introduced without completely redesigning the entire solution composition, thereby extending graft survival time while maintaining relative solution simplicity through modular addition of the active pharmacological agent
3Productivity
If preserving drugs are administered to extend graft survival, then the pool of available donors is augmented, but the risk of primary graft dysfunction increases without effective treatment
Solution Approach 1:
The patent employs PPARα agonists as transient, short-acting pharmacological agents that provide immediate protective effects during the critical period of organ preservation and early post-transplant survival. These agents act as disposable protective measures that prevent primary graft dysfunction without requiring long-term commitment, thereby safely expanding the donor pool by enabling preservation and recovery of organs that would otherwise be unsuitable
Data Source
AI summary
Methods and compositions for reducing, preventing or reversing organ damage and/or enhancing organ preservation by administration of a peroxisome-proliferator activated receptor-alpha (PPARα) agonist to the organ.